Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
azacitidine + epacadostat + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Incyte
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous, Subcutaneous
01
Overview
A combination therapy consisting of azacitidine (an epigenetic agent), epacadostat (an IDO1 inhibitor), and pembrolizumab (a PD-1 inhibitor). This regimen was designed to enhance anti-tumor immune responses through multiple mechanisms: azacitidine triggers interferon responses and serves as an immunotherapy priming method, epacadostat inhibits IDO1 (an enzyme that contributes to tumor immune intolerance), and pembrolizumab blocks PD-1 to enhance T-cell mediated immune responses against tumors.
- Brand names
- KEYTRUDAVidaza
- Other names
- INCB024360INCB-024360INCB 024360MK-3475MK3475MK 3475
02
Targets
DNMT1 (DNA (cytosine-5)-methyltransferase 1)IDO1 (Indoleamine 2,3-dioxygenase 1)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on azacitidine + epacadostat + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on azacitidine + epacadostat + pembrolizumab.